Matthew Schwee

Cooley advised Abnormal Security, the leader in AI-native human behavior security, on its $250 million Series D financing at a $5.1 billion valuation.

Cooley advised Sword Health, pioneer of the AI Care platform, which uses artificial intelligence to power the delivery of care, on its raise of $130 million in a mix of primary and secondary sales.

Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.

Cooley advised Impact Analytics, a provider of the industry’s most innovative retail, grocery, consumer packaged goods, and supply chain-focused planning and merchandising software suite, on the close of its $40 million growth financing.

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company, on its oversubscribed $225 million Series C financing.